Menu
Not yet recruiting NCT07360288

Efficacy and Safety of TC011 in Relapsed or Refractory Follicular Lymphoma

Phase II Interventional Follicular Lymphoma (FL)

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: TC011 single-arm.
Who it may be relevant to
Registry conditions: Follicular Lymphoma (FL). Basic parameters: from 19 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Center list to be confirmed — check the primary protocol.
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

A Multi-center, Single-arm, Open-label Phase II Study to Evaluate the Efficacy and Safety of TC011 in Patients With Relapsed or Refractory Follicular Lymphoma

Overview

This Phase II, multi-center, single-arm, open-label study evaluates the efficacy and safety of TC011, a CD19-targeted CAR-T cell therapy, in adult patients with relapsed or refractory follicular lymphoma (Grade 1, 2, or 3a). The primary endpoint is objective response rate (ORR) assessed by independent review using the Lugano 2014 classification.

Detailed description

This is a multi-center, single-arm, open-label Phase II clinical trial designed to evaluate the efficacy and safety of TC011, a CD19-targeted chimeric antigen receptor T-cell (CAR-T) therapy, in adult patients with relapsed or refractory follicular lymphoma.

Eligible patients who meet all inclusion and exclusion criteria will undergo leukapheresis for the manufacture of TC011, followed by lymphodepleting chemotherapy and a single intravenous infusion of TC011. Patients will be followed according to the study schedule to assess efficacy and safety outcomes.

The primary efficacy endpoint is objective response rate assessed by independent review using standardized response criteria. Secondary endpoints include additional efficacy measures and safety evaluations. Exploratory assessments may include characterization of TC011-related cellular kinetics and biomarker analyses.

An independent Data Safety Monitoring Board will periodically review accumulated safety and efficacy data to ensure patient safety throughout the study.

Interventions

  • Biological TC011 single-arm
    CD19-targeted chimeric antigen receptor T-cell therapy

Primary outcome measures

  • Objective Response Rate (ORR) [Time frame: Up to 96 weeks]
Secondary outcome measures (8)
  • Complete Response Rate (CRR) [Time frame: Up to 96 weeks]
  • Disease Control Rate (DCR) [Time frame: Up to 96 weeks]
  • Stable Disease Rate (SDR) [Time frame: Up to 96 weeks]
  • Duration of Response (DOR) [Time frame: Up to 96 weeks]
  • Time to Response (TTR) [Time frame: Up to 96 weeks]
  • Progression-Free Survival (PFS) [Time frame: Up to 96 weeks]
  • Overall Survival (OS) [Time frame: Up to 96 weeks]
  • Incidence and severity of adverse events [Time frame: Up to 96 weeks]

Eligibility criteria

Inclusion criteria

  • Ability to provide written informed consent.
  • Age ≥19 years at the time of screening.
  • Histologically confirmed follicular lymphoma Grade 1, 2, or 3a according to WHO 2017 classification.
  • Relapsed or refractory disease after at least two prior systemic therapies including rituximab.
  • ECOG performance status ≤2.
  • Life expectancy ≥12 weeks.
  • At least one measurable lesion (long diameter ≥1.5 cm).
  • Adequate hepatic, renal, hematologic, pulmonary, and cardiac function.
  • Eligible for leukapheresis and successful manufacture of TC011.
  • Agreement to use effective contraception for at least 6 months after TC011 infusion.

Exclusion criteria

  • Histologic transformation to diffuse large B-cell lymphoma or follicular lymphoma Grade 3b.
  • Unresolved ≥Grade 2 toxicity from prior anticancer therapy (excluding hematologic abnormalities).
  • Active or prior malignancy within 2 years, except adequately treated non-melanoma skin cancer or carcinoma in situ.
  • Clinically significant cardiovascular disease within 6 months prior to screening.
  • Active central nervous system involvement by lymphoma.
  • Active uncontrolled infection, including HBV, HCV, HIV, or syphilis (protocol-defined exceptions apply).
  • Active autoimmune or inflammatory neurologic disease.
  • Rapidly progressive disease requiring urgent therapy.
  • Prior treatment with anti-CD19 therapy, adoptive T-cell therapy, gene therapy, or allogeneic stem cell transplantation.
  • Major surgery within 4 weeks prior to screening.
  • Use of investigational agents within 4 weeks prior to screening.
  • Known hypersensitivity to components of TC011.
  • Pregnant or breastfeeding women.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Treatment

Study locations

Center list to be confirmed — check the primary protocol.

Identifiers

NCT: NCT07360288 · TC011_FL_201

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗